Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 300

1.

Clinical course and side effects of anti-IgE monoclonal antibody in patients with severe persistent asthma.

Yalcin AD, Bisgin A, Cetinkaya R, Yildirim M, Gorczynski RM.

Clin Lab. 2013;59(1-2):71-7.

PMID:
23505909
2.

The economic value of anti-IgE in severe persistent, IgE-mediated (allergic) asthma patients: adaptation of INNOVATE to Sweden.

Dewilde S, Turk F, Tambour M, Sandström T.

Curr Med Res Opin. 2006 Sep;22(9):1765-76.

PMID:
16968580
3.

RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.

Zietkowski Z, Skiepko R, Tomasiak-Lozowska MM, Lenczewska D, Bodzenta-Lukaszyk A.

Int Arch Allergy Immunol. 2011;154(1):25-32. doi: 10.1159/000319205.

PMID:
20664274
4.

Monitoring free serum IgE in severe asthma patients treated with omalizumab.

Korn S, Haasler I, Fliedner F, Becher G, Strohner P, Staatz A, Taube C, Buhl R.

Respir Med. 2012 Nov;106(11):1494-500. doi: 10.1016/j.rmed.2012.07.010.

5.

Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).

Rubin AS, Souza-Machado A, Andradre-Lima M, Ferreira F, Honda A, Matozo TM; QUALITX Study Investigators..

J Asthma. 2012 Apr;49(3):288-93. doi: 10.3109/02770903.2012.660297.

PMID:
22356355
6.

Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma.

Somerville L, Bardelas J, Viegas A, D'Andrea P, Blogg M, Peachey G.

Curr Med Res Opin. 2014 Jan;30(1):59-66. doi: 10.1185/03007995.2013.844115.

PMID:
24028677
7.

Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy.

Holgate ST, Djukanović R, Casale T, Bousquet J.

Clin Exp Allergy. 2005 Apr;35(4):408-16. Review.

PMID:
15836747
8.

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.

Holgate ST, Chuchalin AG, Hébert J, Lötvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD; Omalizumab 011 International Study Group..

Clin Exp Allergy. 2004 Apr;34(4):632-8.

PMID:
15080818
9.
10.

Changes of immunomodulatory cytokines associated with omalizumab therapy for severe persistent asthma.

Shimizu Y, Dobashi K, Fueki N, Fueki M, Okada T, Tomioka S, Makino S, Mori M.

J Biol Regul Homeost Agents. 2011 Apr-Jun;25(2):177-86.

PMID:
21880206
11.

[Omalizumab treatment in patients with asthma: summary of Meir Medical Center experience with 47 patients].

Shitrit D, Talker O, Metabichek A, Yaakovi I.

Harefuah. 2012 Apr;151(4):216-9, 254, 253. Hebrew.

PMID:
22616149
12.

Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study.

Maselli DJ, Singh H, Diaz J, Peters JI.

Ann Allergy Asthma Immunol. 2013 Jun;110(6):457-61. doi: 10.1016/j.anai.2013.04.011.

PMID:
23706716
13.

Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.

Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, Woolacott N.

Pharmacoeconomics. 2012 Nov 1;30(11):991-1004. doi: 10.2165/11597160-000000000-00000. Review.

PMID:
22950547
14.

Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase.

Maurer M, Altrichter S, Bieber T, Biedermann T, Bräutigam M, Seyfried S, Brehler R, Grabbe J, Hunzelmann N, Jakob T, Jung A, Kleine-Tebbe J, Mempel M, Meurer M, Reich K, Ruëff F, Schäkel K, Sengupta K, Sieder C, Simon JC, Wedi B, Zuberbier T, Mahler V, Staubach P.

J Allergy Clin Immunol. 2011 Jul;128(1):202-209.e5. doi: 10.1016/j.jaci.2011.04.038.

PMID:
21636116
15.

Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients.

Riccio AM, Dal Negro RW, Micheletto C, De Ferrari L, Folli C, Chiappori A, Canonica GW.

Int J Immunopathol Pharmacol. 2012 Apr-Jun;25(2):475-84.

PMID:
22697079
16.

Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs.

Costello RW, Long DA, Gaine S, Mc Donnell T, Gilmartin JJ, Lane SJ.

Ir J Med Sci. 2011 Sep;180(3):637-41. doi: 10.1007/s11845-011-0716-2.

PMID:
21557095
17.
18.

Changes in total IgE plasma concentration measured at the third month during anti-IgE treatment predict future exacerbation rates in difficult-to-treat atopic asthma: a pilot study.

Dal Negro RW, Guerriero M, Micheletto C, Tognella S, Visconti M.

J Asthma. 2011 Jun;48(5):437-41. doi: 10.3109/02770903.2011.578316.

PMID:
21599560
19.
20.

Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments.

Pelaia G, Vatrella A, Busceti MT, Gallelli L, Terracciano R, Maselli R.

Curr Drug Targets. 2015;16(2):171-8. Review.

PMID:
25523898
Items per page

Supplemental Content

Support Center